Heather Losey, PhD on ALKS 4230

Heather Losey, PhD on ALKS 4230

Cancer-News

1 month
60 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.

Read here: https://jitc.bmj.com/content/8/1/e000673

Up Next Autoplay